Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04550442
Status:
RECRUITING
Last Update Posted:
2024-04-23
First Post:
2020-09-09
Brief Title:
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-09-04
Start Date Type:
ACTUAL
Primary Completion Date:
2025-05-11
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-05-11
Completion Date Type:
ESTIMATED
First Submit Date:
2020-09-09
First Submit QC Date:
September 9 2020
Study First Post Date:
2020-09-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-22
Last Update Post Date:
2024-04-23
Last Update Post Date Type:
ACTUAL